resume-cv 1_may_2015

42
1 Charles M. Beasley, Jr., M.D. 8161 Beech Knoll Indianapolis, IN 46256-2107 +1.317.435.5330 Mobile [email protected] First-tier, executive level experience in the design, conduct, analysis, and successful submission of multiple Phase II-IV development programs. Additional work with select Phase I studies in various areas especially cardiac electrophysiology assessment. Extensive experience in the domain of drug safety evaluation in response to high-profile challenges to the safety profiles of several drugs. Published widely in the scientific literature while in industry, gaining the respect of the academic community as exemplified by being elected to the highly competitive and prestigious American College of Neuropsychopharmacology. Training and research in computer science and statistics facilitate accurate and efficient collaboration with data scientists and statisticians, enhancing quality in progressing from study protocols to submissions and scientific manuscripts. PROFESSIONAL POSITIONS Eli Lilly and Company July 1987-30/Apr/2015 Global Patient Safety (GPS) April 2004-30/Apr/2015 Distinguished Lilly Scholar (Vice-Presidential level)Oct. 2004-30/Apr/2015 Distinguished Lilly Fellow April 2004-Oct. 2004 Consulted for individual projects to the Vice-President GPS and Medical Director GPS Engaged in activities relevant to the assessment of drug safety of my choosing Designed comprehensive assessments incorporated work ranging from in vitro research, through toxicology, Phase 1 studies, clinical trials (Phase II- IV), post-marketing surveillance, and large database pharmacoepidemiology studies tailored to address topics of special relevance for select drugs (additional detail confidential) Performed in-depth due diligence from a safety perspective for potential collaboration molecules Internal committee participation

Upload: charles-m-beasley-jr-md

Post on 07-Apr-2017

154 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Resume-CV 1_May_2015

1

Charles M. Beasley, Jr., M.D.8161 Beech Knoll

Indianapolis, IN 46256-2107+1.317.435.5330 Mobile

[email protected]

First-tier, executive level experience in the design, conduct, analysis, and successful submission of multiple Phase II-IV development programs.  Additional work with select Phase I studies in various areas especially cardiac electrophysiology assessment.  Extensive experience in the domain of drug safety evaluation in response to high-profile challenges to the safety profiles of several drugs.  Published widely in the scientific literature while in industry, gaining the respect of the academic community as exemplified by being elected to the highly competitive and prestigious American College of Neuropsychopharmacology.  Training and research in computer science and statistics facilitate accurate and efficient collaboration with data scientists and statisticians, enhancing quality in progressing from study protocols to submissions and scientific manuscripts.

PROFESSIONAL POSITIONSEli Lilly and Company July 1987-30/Apr/2015

Global Patient Safety (GPS) April 2004-30/Apr/2015Distinguished Lilly Scholar (Vice-Presidential level) Oct. 2004-30/Apr/2015Distinguished Lilly Fellow April 2004-Oct. 2004

Consulted for individual projects to the Vice-President GPS and Medical Director GPS Engaged in activities relevant to the assessment of drug safety of my choosing Designed comprehensive assessments incorporated work ranging from in vitro research, through

toxicology, Phase 1 studies, clinical trials (Phase II-IV), post-marketing surveillance, and large database pharmacoepidemiology studies tailored to address topics of special relevance for select drugs (additional detail confidential)

Performed in-depth due diligence from a safety perspective for potential collaboration molecules Internal committee participation

o Global Product Labeling Committee: committee making final decisions regarding contents of Core Data Sheets (CDSs) for drugs

o Hepatic Safety Advisory Committeeo Cardiovascular Safety Advisory Committee (CvSAC) o ECG Sub-Committee (of CvSAC)o Psychobehavioral Advisory Committeeo Laboratory Data Analysis Working Groupo Adverse Events Analysis Working Groupo Standards Control Board: group assuring that data collection / case report forms are

consistent with CFAST/CDISC standards Participated in design, analysis, and interpretation of Thorough QT (TQT) studies Developed revised and consistent reference limits for numerical hemodynamic parameters and

quantitative ECG findings Revised the set of possible qualitative ECG findings used during the interpretation of qualitative ECG

observations to minimize ambiguity and inconsistency across ECGs

Page 2: Resume-CV 1_May_2015

2

Contributed to revision of interpretive standards (i.e., diagnostic criteria) for the set of possible qualitative ECG findings and documented academic literature supporting those interpretive standards

Designed the analytical methods resulting in summary statistical tables for qualitative ECG data Supervised extensive research on reference limits for standard safety laboratory analytes optimized

for use in analysis of outliers in randomized clinical trials, in contrast to limits optimized for individual patient care (research ongoing)

Authored the clinical sections of the external CFAST/CDISC Therapeutic Area for TQT Studies Served as an author for a cross-industry PhUSE whitepaper recommending standard analyses for

TQT studies Collaborated with statisticians to design the standardized analyses and output for the Summaries of

Clinical Safety / Integrated Summaries of Safety for NDAs / European submissions / internal major safety update reviews

Developed internal standardized methods for use of data from multiple clinical trials in the development of the list of adverse reactions for incorporation into CDSs

Worked hands-on with most teams bringing molecules forward for initial submission and therefore CDS with organization of studies, their analysis, and interpretation with regard to identifying Adverse Reactions

Authored / co-authored several academic manuscripts in the areas of QT, assessment methods in drug safety, safety topics for specific drugs

Designed a Phase I study to sensitively assess weight gain potential for a new molecular entity

Neuroscience Business Unit Jan. 2003-April 2004Distinguished Lilly Fellow

Consulted to the President of the Business Unit Was available for consultation to other therapeutic area business units on matters of both efficacy

(experimental design) and safety (methods of assessment, interpretation) Designed comprehensive assessments that incorporated work ranging from in vitro research, through

toxicology, Phase 1 studies, clinical trials (Phase II-IV), post-marketing surveillance, and large database phrmacoepidemiology studies tailored to address topics of special relevance for select drugs (additional detail confidential)

Consulted to the program phase development teams developing metabotropic glutamate receptor platform compounds as antipsychotics and a selective norepinephrine uptake inhibitor as an adjunctive antidepressant in depression non-responsive to a serotonin uptake inhibitor

Tadalafil (Cialis®) Product Team July 2001-Jan. 2003Distinguished Lilly Fellow and Medical Director

Supervised the design and execution of all activities required to achieve regulatory approval in the EU and the US for tadalafil for the treatment of erectile dysfunction subsequent to the initial US NDA and EU submission documents

Planned analyses to address multiple and distinct questions from both US and European regulators regarding tadalafil submission as well as a multiple component plan to address a topic of special interest to European regulators (additional detail confidential)

Designed additional Phase I studies to support the initial indication for tadalafilo Length of activity study to document activity for at least 36 hourso Interaction with nitrates study to demonstrate magnitude of effect under controlled and safe

circumstances

Page 3: Resume-CV 1_May_2015

3

o Interaction with alcohol study to demonstrate magnitude of any additive hypotensive effecto TQT study

Designed and initiated Phase IV studies intended to support the commercialization of tadalafil in the treatment of erectile dysfunction

Outlined potential development programs for tadalafil in the treatment of additional indications, including diabetic gastroparesis, benign prostatic hypertrophy, and pulmonary hypertension

Directly supervised and managed 4 physicians in support of the activities listed above

Olanzapine (Zyprexa®) Product Team Jan. 1995-July 2001Distinguished Lilly Fellow July 1999-July 2001Medical Advisor Jan. 1995-July 1999

Following US and European approval of olanzapine for schizophrenia / psychosiso Consulted on additional olanzapine indication development programs: various phases of

bipolar disorder, dementia / manifestations of dementia and alternative formulation development programs: rapidly dissolving tablet, rapid acting intramuscular formulation

o Designed and executed the study to demonstrate maintenance / long-term antipsychotic efficacy of olanzapine

o Supervision and assessment of any and all safety topics of special relevance regarding olanzapine that included developed multiple in-depth safety reports for safety topics of special relevance for olanzapine and interacted with US and international regulatory authorities with regard to these topics with successful outcomes (additional detail confidential)

o Participated in design of glycemic clamp studies to assess impact of olanzapine on glycemic control

o Interface with Japanese investigators and direct planning and writing of Japanese olanzapine submission (Giyo) for schizophrenia

o Management of all clinical aspects of initial Japanese development program for olanzapineo Consulted to marketing on post-approval activities for olanzapineo Transitional team leader for metabotropic glutamate receptor platformo Designed and executed a successful Phase III study for a metabotropic glutamate receptor

compound after 5 failed Phase II studies Prior to US and European approval for schizophrenia / psychosis

o Supervised the analysis and writing of US and European regulatory submission documents for olanzapine that resulted in simultaneous approval in 13 months following submissions

o Consulted to marketing on preapproval activities for olanzapine

Neuroscience / Psychopharmacology Division of Clinical Investigation July 1987-Jan. 1995Senior Clinical Research Physician March 1992-Jan. 1995Research Physician Aug. 1989-March 1992Associate Clinical Research Physician July 1987-Aug.1989

Olanzapine Phaseo Oversaw all medical aspects of design and implementation of the 5 Phase II-III studies for

olanzapine in the treatment of psychosis / schizophrenia Fluoxetine (Prozac®) and tomoxetine Phase

Page 4: Resume-CV 1_May_2015

4

o Had overall medical responsibility for fluoxetine including efficacy, safety, advancement of scientific understanding and marketing support, including design and execution of 10 Phase IV studies

o Had overall medical responsibility for Phase III development tomoxetine as an antidepressant (program terminated and molecule developed with generic name atomoxetine [Strattera®] for attention deficit hyperactivity disorder), including design and execution of 3 Phase II studies

o Initiated a program for publication of multiple never-published fluoxetine study results as well as post-hoc data mining from fluoxetine studies to clarify important clinical and scientific aspects of the activity of fluoxetine in order to increase medical knowledge of fluoxetine, provide marketing support, and increase personal academic stature

o Successfully lead the data analysis effort in 1990-1991 to clarify and rebut, if warranted, the assertion that fluoxetine induces suicidal ideation of unique clinical characteristics and distinct from other antidepressants

o Conducted in-depth review and evaluation of the problem of placebo response in antidepressant trials

o Completed routine regulatory safety review documents for fluoxetine and prepared special reports to address safety topics of special relevance for fluoxetine

o Provided marketing support and review for fluoxetine

Group Health Associates, Cincinnati, OH May 1987-June 1987 Physician, Psychiatric Disorders

Eating Disorders Center, Cincinnati Medical Center July 1985-March 1987Consultant, Medical Support for Bulimia Clinical Trial, Psychiatry Dept.

Affective Disorders Center, University Of Cincinnati Medical Center June 1985-May1986Physician, Sub-Investigator for Antidepressant Clinical Trial, Psychiatry Dept.

Neuropsychology Laboratory, Yale University School of Medicine July 1978-Aug.1979Associate In Research, Database And Software Designer, Neurology Dept.

Dept. Psychology, Yale University June 1977-July 1978Research Programmer, Software Developer in Machine Learning Artificial Intelligence Research

ACADEMIC APPOINTMENTSVoluntary Assistant Professor Jan. 1989-June 1996Department of Psychiatry, University of Cincinnati

POSTGRADUATE TRAININGUniversity of Cincinnati 1984-87Department of Psychiatry; PGY-II-IV, General Psychiatry residencyYale University 1983-84

Page 5: Resume-CV 1_May_2015

5

1983-84Department of Psychiatry; PGY-I Flexible intern at the Hospital of St. Raphael

EDUCATION M.D., University of Kentucky College of Medicine 1983

1983B.A., Psychology Yale University 1977

CERTIFICATION AND LICENSURENational Board of Medical Examiners Diplomate 1984American Board of Psychiatry and Neurology Diplomate (Psychiatry) 1988Medical License: Ohio; Indiana; Maine

AWARDS AND HONORSSandoz Pharmacology Award 2nd year medical schoolPromoted with distinction 2nd and 3rd years medical schoolElected to AOA and AOA president 3rd year medical schoolAMA-ERF Rock Sleyster Memorial Scholar 4th year medical schoolCornelia B. Wilbur Psychiatry Departmental Award 4th year medical schoolNeurology Departmental Award 4th year medical schoolGraduated medical school with high distinction 1983Laughlin Fellow American College of Psychiatrists, 19871st place, Maurice Levine Essay Award Cincinnati Psychiatric Society, 19874th Year Resident’s Award Department of Psychiatry, University of Cincinnati, 1987Resident’s Research Award Department of Psychiatry, University of Cincinnati, 1987Founder’s Day Resident Award Paper Ohio Psychiatric Association, 1987

PROFESSIONAL SOCIETY FELLOWSHIPSAmerican Psychiatric AssociationAmerican College of PsychiatristsAmerican College of NeuropsychopharmacologyRoyal College of Physicians of the United Kingdom

PROFESSIONAL SOCIETY MEMBERSHIPSIndiana Psychiatric SocietyAmerican Federation for Clinical ResearchAmerican Society of Clinical Psychopharmacology

EDITORIAL BOARD MEMBERSHIPSSection Editor, Psychopharmacology The Open Pharmacology JournalEditorial Board Current PsychopharmacologyEditorial Board World Journal of PsychiatryEditorial Board The Scientific World JournalEditorial Board ISRN PsychiatryEditorial Board Journal of Cardiovascular Disorders

REVIEWERJournal of Clinical PsychopharmacologyArchives of General PsychiatryPsychological Bulletin

Page 6: Resume-CV 1_May_2015

6

Psychological MedicineBiological PsychiatryNeuropsychiatric Diseases and TreatmentProgress in Nero-Psychopharmacology & Biological PsychiatryAmerican Journal of Psychiatry

OTHER PROFESSIONAL ACTIVITIESCo-chairperson History Committee American College of Neuropsychopharmacology 2008-2010 Co-chairperson PMA Education & Research Institute Pharmacology Training Series: Central Nervous System Pharmacology Washington, D.C. Sep 29-30, 1993Co-chairperson Paper Session 41: Comorbidity in affective disorders American Psychiatric Association Annual Meeting Montreal, Canada May 12, 1988

PATENTS ISSUED5605897       2-Methyl-Thieno-Benzodiazepine (Olanzapine)5817656       Method for Treating Mental Disorders (Olanzapine)5817657       Method for Treating Psychoactive Substance Disorders (Olanzapine)5776928       Method for Treating Dyskinesia (Olanzapine)6071902       Method for Treating Excessive Aggression (Olanzapine)6159963       Method for Treating Substance Abuse (Olanzapine)6274636       Method of Treating Tic Disorder (Olanzapine)6506746       Method for Treating Cognitive Dysfunction (Olanzapine)

BOOK CHAPTERS

1. Beasley C, Grundy S, Gannon K, Berg P

Overview of the safety of olanzapine

In Tran P, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G (Eds.)

Olanzapine (Zyprexa): A Novel Antipsychotic

Philadelphia: Lippincott Williams & Wilkins, 2000

2. Tran P. Sutton V, Beasley C, Tollefson G

Efficacy of olanzapine

In Tran P, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G (Eds.)

Olanzapine (Zyprexa): A Novel Antipsychotic

Philadelphia: Lippincott Williams & Wilkins, 2000

3. Anderson J, Kline P, Beasley C

A general learning theory and its application to schema abstraction

In Bower G (Ed.)

The Psychology of Learning and Motivation, Vol 13.

New York: Academic Press, 1979

Page 7: Resume-CV 1_May_2015

7

4. Anderson J, Kline P, Beasley C

Complex learning processes

In Snow R, Federico P & Montague W (Eds.)

Aptitude, Learning, and Instruction, Vol 2: Cognitive Process Analysis of Learning and Problem

Solving

Hillsdale, NJ: Lawrence Erlbaum and Associates, 1980

ARTICLES

1. Crowe B, Brueckner A, Beasley C, Kulkarni P

Current practices, challenges, and statistical issues with product safety labeling

Statistics in Biopharmaceutical Research 5:180-193; 2013

2. Loghin C, Haber H, Beasley CM, Kothare PA, Kauffman L, April J, jin L, Allen AJ, Mitchell MI

Effect of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers

Br J Clin Pharmacol 75:549-564; 2013

3. Beasley C, Benson C, Xia J, Young S, Haber H, Mitchell M, Loghin C

Systematic decrements in QTc between the first and second day of contiguous daily ECG

recordings under controlled conditions

PACE 34:1116-1127; 2011

4. Millen BA, Campbell GM, Beasley CM

Weight changes over time in adults treated with oral or depot formulations of olanzapine:

a pooled analysis of 86 clinical trials

J Psychopharmacol 25:639-645; 2011

5. Meyer RE, Salzman C, YoingstromEA, ClaytonPJ, Goodwin FK, Mann JJ, Alphs LD, Broich K,

Goodman WK, Greden JF, Meltzer HY, Normand SL, Posner K, Shaffer D, Oquendo MA, Stanley

B, Trivedi MH, Turecki G, Beasley CM, Beautrais AL, Bridge JA, Brown GK, Revicki DA, Ryan

ND, Sheehan DV

Suicidality and risk of suicide – definition, drug safety concerns, and a necessary target

for for drug development: a brief report

J Clin Psychiatry 71:1040-1046; 2010

6. Meyer RE, Salzman C, YoingstromEA, ClaytonPJ, Goodwin FK, Mann JJ, Alphs LD, Broich K,

Goodman WK, Greden JF, Meltzer HY, Normand SL, Posner K, Shaffer D, Oquendo MA, Stanley

B, Trivedi MH, Turecki G, Beasley CM, Beautrais AL, Bridge JA, Brown GK, Revicki DA, Ryan

ND, Sheehan DV

Suicidality and risk of suicide – definition, drug safety concerns, and a necessary target

Page 8: Resume-CV 1_May_2015

8

for for drug development: a consensus statement

J Clin Psychiatry 71:pe1-pe21; 2010

7. Lipkovich I, Jacobson JG, Caldwell C, Hoffman VP, Kryzhanovskaya L, Beasley CM

Early predictors of weight gain risk during treatmentwith olanzapine: analysis of pooled

data from 58 clinical trials

Psychopharm Bull 42:23-39; 2009

8. Beasley CM, Dmitrienko A, Mitchell MI

Design and analysis considerations for thorough QT studies employing conventional (10

s, 12-lead) ECG recordings

Expert Rev Clin Pharmacol 1:815-839; 2008

9. Beasley C, Ball S, Nilsson M, et al

Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data

sources from placebo-controlled trials

J Clin Psychopharmacol 27:682-686; 2007

10. Tauscher-Wisniewski S, Disch, Plewes J, Ball SG, Beasley CM

Evaluating suicidality as an adverse event in clinical trials of fluoxetine treatment for

indications other than major depressive disorder

Psychol Med 37:1-9; 2007

11. Beasley CM, Stauffer VL, Liu-Seifert H, Taylor CC, Dunayevich E, Davis JM,

All-cause treatment discontinuation in schizophrenia during treatmrnt with olanzapine

relative to other antipsychotics: an integrated analysis

J Clin Psychopharmacol 27:252-258; 2007

12. Perlis RH, Beasley CM, Wines JD, Tamura RN, Cusin C, Shear D, Amsterdam J, Quitkin F,

Strong RE, Rosenbaum JF, Fava M

Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of

fluoxetine for major depressive episodes

Psychother Psychosom 76:40-46; 2007

13. Cusin C, Fava M, Amsterdam JD, Quitkin FM, Reimherr FW, Beasley CM, Rosenbaum JF, Perlis

RH

Early symptomatic worsening during treatment with fluoxetine in major depressive

disorder: prevalence and implications

J Clin Psych 68:52-57; 2007

Page 9: Resume-CV 1_May_2015

9

14. Crumb WJ, Ekins S, Darazan RD, Wikel JH, Wrighton SA, Carlson C, Beasley CM

Effects of Antipsychotic Drugs on Ito, INa, Isus, IK1, and hERG: QT prolongation, atructure

activity relationship and network analysis

Pharmacol Res 23:1133-1143; 2006

15. Beasley CM, Sutton VK, Taylor CC, Sethuraman G, Dossenbach M, Naber D

Is quality of life among minimally symptomatic patients with schizophrenia better

following withdrawal or continuation of antipsychotic treatment?

J Clin Psychopharmacol 26:40-44; 2006

16. Carrier S, Brock GB, Pommerville PJ, Shin J, Anglin G, Whitaker JS, Beasley CM

Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile

dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial

J Sexual Med 2:685-698; 2005

17. Beasley CM, Mitchell MI, Dmitrienko AA, Emmick JT, Shen W, Costigan TM, Bedding AW, Turick

MA, Bakhtyari A, Warner MR, Ruskin JN, Cantilena LR, Kloner RA

The combined use of ibutilide as an active control with intensive ECG sampling and signal

averaging as a sensitive method to assess the effects of taalafil on the human QT interval

J Am Coll Cardiol 46:678-687; 2005

18. Young JM, Feldman RA, Auerbach SM, Kaufman JM, Garcia CS, Shen W, Murphy AM, Beasley

CM, Hague JA, Ahuja S

Tadalafil improved erectile function at 24 and 36 hours after dosing: US trial

J of Andrology 26:310-318; 2005

19. Sarazan RD, Crumb WJ, Beasley CM, Emmick JT, Ferguson KM, Strnat CA, Sausen PJ

Absence of clinically important HERG channel blockade by three compounds that inhibit

phosphodiesterase 5 – sildenafil, tadalafil, and vardenafil

E J Pharmacology 502:163-167; 2004

20. Von Keitz A, Rajfer J, Segal S, Murphy A, Denne J, Costigan T, Lockhart D, Beasley C, Emmick J

A multicenter, randomized, double-blind, crossover study to evaluate patient preference

between tadalafil and sildenafil

Eu Urology 45:499-507; 2004

21. Beasley C, Sutton V, Hamilton S, Walker D, Dossenbach M, Taylor C, Alaka K, Bykowski D,

Tollefson G

A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of

Page 10: Resume-CV 1_May_2015

10

psychotic relapse

J Clin Psychopharmacol 23:582-594; 2003

22. Helstrom WJG, Overstreet JW, Yu A, Saikali K, Shen W, Beasley, CM, Watkins VS

Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones

J Urology 170:887-891; 2003

23. Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM

An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients

with schizophrenia during olanzapine clinical trials: comparisons with placebo,

haloperidol, risperidone, or clozapine

J Clin Psychiatry 64:898-906; 2003

24. Lindborg S, Beasley C, Alaka K, Taylor C

Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in

acutely agitated patients

Psychiatry Res 119:113-123; 2003

25. Quitkin F, Petkova E, McGrath P, Taylor B, Beasley C, Stewart J, Amsterdam J, Fava M,

Rosenbaum J, Reimherr F, Fawcett J, ChenY, Klein D

When should a trial of fluoxetine for major depression be declared failed?

Am J Psychiatry 160:734-740; 2003

26. Inada T, Beasley C, Tanaka Y, Walker D

Extrapyramidal symptom profiles assessed with DIEPSS: comparison with western scales

in the clinical double-blind studies of schizophrenic patients treated with either olanzapine

or haloperidol

Intl Clin Psychopharmacol 18:39-48; 2003

27. Sowell M, Mukhopadhyay N, Cavazzoni P, Shankar S, Steinberg H, Breier, Breier A, Beasley C,

Dananberg J

Hyperglycemic clamp assessment of insulin secretory responses in normal subjects

treated with olanzapine, risperidone, or olanzapine. J

Clin Endocrinology and Metab 87:2918-2923; 2002

28. Meehan K, Wang H, David S, Nisivoccia J, Jones B, Beasley C, Feldman P, Mintzer J, Beckett L,

Breier A

Comparison of rapidly acting intramuscular olanzapine, lorazxepam, and placebo: a

double-blind, randomized study in acutely agitated patients with dementia

Neuropsychopharmacology 26:494-504; 2002

Page 11: Resume-CV 1_May_2015

11

29. Brunswick D, Amsterdeam J, Fawcett J, Quitkin F, Reimherr, Rosenbaum J, Beasley C

Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment

J Affect Diord 68:243-249; 2002

30. Kennedy J, Bymaster F, Schuh L, Calligaro D, Nomikos G, Felder C, Bernauer B, Kinon B, Baker

R, Hau D, Roth H, Dossenbach M, Kaiser C, Beasley C, Holcombe J, Effron M, Breier A

A current review of olanzapine’s safety in the geriatric patient: from pre-clinical

pharmacology to clinical data

Int J Geriatr Psychiatry 16:S33-S61; 2001

31. Brunswick D, Amsterdeam J, Fawcett J, Quitkin F, Reimherr, Rosenbaum J, Beasley C

Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy

J Clin Psychopharmacol 21:616-618; 2001

32. Czekalla J, Beasley C, Dellva M, Berg P, Grundy S

Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia

and related psychosis

J Clin Psychiatry 62:191-198; 2001

33. Czekalla J, Kollack-Walker S, Beasley C

Cardiac Safety Parameters of Olanzapine: comparison with other atypical and typical

antipsychotics

J Clin Psychiatry 62:suppl 2:35-40; 2001

34. Czekalla J, Beasley CM, Ditmann RW, Helsberg K, Kollack-Walker S

Kardiale verträglichkeit unter nueroleptika: vergleichende übersicht zu Qtc-parametern

und assoziierten effekten unter olanzapin und anderen atypischen sowie typischen

antipsychotika

Nervenheilkunde 20:194-201; 2001

35. Perry P, Lund B, Sanger T, Beasley C

Olanzapine plasma concentrations and clinical response: acute phase results of the North

American olanzapine trial

J Clin Psychopharmacol 21:14-20; 2001

36. Beasley C, Koke S, Nilsson M, Gonzales J

Adverse events and treatment discontinuations in clinical trials of fluoxetine in major

depressive disorder: an updated meta-analysis

Clin Ther 22:1319-1330; 2000

Page 12: Resume-CV 1_May_2015

12

37. Voss S, Sanger T, Beasley C

Hematologic reference ranges in a population of patients with schizophrenia

J Clin Psychopharmacol 20:653-657, 2000

38. Beasley C, Nilsson M, Koke S, Gonzales J

Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of

major depression: a meta-analysis of the 20-mg/day dose

J Clin Psychiatry 61:722-728; 2000

39. McGrath P, Stewart J, Petkova E, Quitkin F, Amsterdam J, Fawcett J, Reimherr F, Rosenbaum J,

Beasley C

Predictors of Relapse During Fluoxetine Continuation or Maintenance Treatment of Major

Depression

J Clin Psychiatry 61:518-524; 2000

40. Michelson D, Amsterdam J, Quitkin F, Reimherr F, Rosenbaum J, Zajecka J, Sundell K, Kim Y,

Beasley C

Changes in Weight During a 1-Year Trial of Fluoxetine

Am J Psychiatry 156:1170-1176; 1999

41. Revicki D, Genduso L, Hamilton S, Ganoczy D, Beasley C

Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic

disorders: Quality of life and clinical outcomes of a randomized clinical trial

Qual Life Res 8:417-426; 1999

42. Amsterdam J, Garcia-Espana F, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, Beasley C

Fluoxetine efficacy in menopausal women with and without estrogen replacement

J Affect Disord 55:11-17; 1999

43. Callaghan J, Bergstrom R, Ptak L, Beasley C

Olanzapine: pharmacokinetic and pharmacodynamic profile

Clin Pharmacokinet 37:177-193; 1999

44. Amsterdam J, Garcia-Espana F, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, Beasley C

Blood pressure changes during short-term fluoxetine treatment

J Clin Psychopharmacol 19:9-14; 1999

45. Zajecka J, Amsterdam J, Quitkin F, Reimberr F, Rosenbaum J, Tamura R, Sundell K, Michelson

D, Beasley C

Changes in adverse events reported by patients during 6 months of fluoxetine therapy

J Clin Psychiatry 60:389-394; 1999

Page 13: Resume-CV 1_May_2015

13

46. Beasley C, Dellva M, Tamura R, Morgenstern H, Glazer W, Ferguson K, Tollefson G

Randomized double-blind comparison of the incidence of tardive dyskinesia in patients

with schizophrenia during long-term treatment with olanzapine or haloperidol

Br J Psychiatry 174:23-30; 1999

47. Tran P, Tollefson G, Sanger T, Lu Y, Berg P, Beasley C

Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and

long-term therapy

Br J Psychiatry 174:15-22; 1999

48. Sanger T, Lieberman J, Tohen M, Grundy S, Beasley C, Tollefson G

Olanzapine versus haloperidol treatment in first episode psychosis

Am J Psychiatry 156:79-87; 1999

49. Amsterdam J, Garcia-Espana F, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, Schweizer E,

Beasley C

Efficacy and Safety of Fluoxetine in Treating Bipolar II Major Depressive Episode

J Clin Psychopharmacol 18:435-440; 1998

50. Reimherr F, Amsterdam J, Qutikin F, Rosenbaum J, Fava M, Zajecka J, Beasley C, Michelson D,

Roback P, Sundell K

Optimal length of continuation therapy in depression: a prospective assessment during

long-term fluoxetine treatment

Am J Psychiatry 155:1247-1253; 1998

51. Beasley C

Olanzapine: recent clinical findings and increased patient benefits

Japanese J Clin Psychopharmacol 1:759-765; 1998

52. Tollefson G, Sanger T, Beasley C, Tran P

A double-blind, controlled comparison of the novel antipsychotic olanzapine versus

haloperidol or placebo on anxious and depressive symptoms accompanying

schizophrenia

Biol Psychiatry 43:803-810; 1998

53. Tran P, Dellva M, Tollefson G, Wentley A, Beasley C

Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and

related psychoses

Br J Psychiatry 172:499-505; 1998

54. Zajecka J, Fawcett J, Amsterdam J, Quitkin F, Reimherr F, Rosenbaum J, Michelson D, Beasley

C

Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study

J Clin Psychopharmacol 18:193-197; 1998

Page 14: Resume-CV 1_May_2015

14

55. Stewart J, Quitkin F, McGrath P, Amsterdam J, Fava M, Fawcett J, Reimherr F, Rosenbaum J,

Beasley C, Roback P

Use of pattern analysis to predict differential relapse of remitted patients with major

depression during 1 year of treatment with fluoxetine or placebo

Arch Gen Psychiatry 55:334-343; 1998

56. Hamilton S, Revicki D, Genduso L, Beasley C

Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North

American double-blind Trial

Neuropsychopharmacology 18:41-49; 1998

57. Perry P, Sanger T, Beasley C

Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic

patients

J Clin Psychopharmacol 17:472-477; 1997

58. Dellva M, Tran P, Tollefson G, Wentley A, Beasley C

Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance

treatment of schizophrenia

Psychiatric Services 48:1571-1577; 1997

59. Goldstein D, Hamilton S, Masica D, Beasley C

Fluoxetine in Medically Stable, Depressed Geriatric Patients: Effects on Weight

J Clin Psychopharmacol 17:365-369; 1997

60. Crawford A, Beasley C, Tollefson G

The acute and long-term effect of olanzapine compared with placebo and haloperidol on

serum prolactin concentrations

Schizophrenia Res 26:41-54; 1997

61. Tran P, Hamilton S, Kuntz A, Potvin J, Andersen S, Beasley C, Tollefson G

Double-blind comparison of olanzapine versus risperidone in the treatment of

schizophrenia and other psychotic disorders

J Clin Psychopharmacol 17:407-418; 1997

62. Tollefson G, Beasley C, Tamura R, Tran P, Potvin J

Blind, controlled, long-term study of the comparative incidence of treatment-emergent

tardive dyskinesia with olanzapine or haloperidol

Am J Psychiatry 154:1248-1254; 1997

Page 15: Resume-CV 1_May_2015

15

63. Beasley C, Tollefson G, Tran P

Safety of olanzapine

J Clin Psychiatry 58:Suppl 10:13-17; 1997

64. Beasley C, Tollefson G, Tran P

Efficacy of olanzapine: an overview of pivotal clinical trials

J Clin Psychiatry 58:Suppl 10:7-12; 1997

65. Blumenfield M, Levy N, Spinowitz B, Charytan C, Beasley C, Dubey A, Solomon R, Todd R,

Goodman A, Bergstrom R

Fluoxetine in depressed patients on dialysis

Intl J Psychiatry in Medicine 27:71-80; 1997

66. Beasley C, Hamilton S, Crawford A, Dellva M, Tollefson G, Tran P, Blin O, Beuzen J

Olanzapine versus haloperidol: acute phase results of the international double-blind

olanzapine trial

Euro Neuropsychopharmacol 7:125-137; 1997

67. Amsterdam J, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, Michelson D, Hornig-Rohan M,

Beasley C

Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter

study

Am J Psychiatry 154:963-969; 1997

68. Tran P, Dellva M, Tollefson G, Beasley C, Potvin J, Kiesler G

Extrapyramidal Symptoms and tolerability of olanzapine versus haloperidol in the acute

treatment of schizophrenia

J Clin Psychiatry 58:205-211; 1997

69. Tollefson G, Beasley C, Tran P, Street J, Kruger J, Tamura R, Graffeo K, Thieme M

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and

schizophreniform disorders: results of an international collaborative trial

Am J Psychiatry 154:457-465; 1997

70. Beasley C

Safety of olanzapine

J Clin Psychiatry Monograph 15:2:19-21; 1997

71. Beasley C

Efficacy of olanzapine

J Clin Psychiatry Monograph 15:2:17-19; 1997

Page 16: Resume-CV 1_May_2015

16

72. Levy N, Blumenfield M, Beasley C, Dubey A, Solomon R, Todd R, Goodman A, Bergstrom R

Fluoxetine in depressed patients with renal failure and in depressed patients with normal

kidney function

Gen Hosp Psychiatry 18:8-13; 1996

73. Beasley C, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

Psychopharmacology 124:159-167; 1996

74. Beasley C, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S

Olanzapine versus placebo and haloperidol: acute phase results of the North American

double-blind olanzapine trial

Neuropsychopharmacol 14:111-123; 1996

75. Tollefson G, Rampey A, Beasley C, Enas G, Potvin J

Absence of a relationship between adverse events and suicidality during

pharmacotherapy for depression

J Clin Psychopharmacol 14:163-169; 1994

76. Tollefson G, Fawcett J, Winokur G, Beasley C, Potvin J, Faries D, Rampey A, Sayler M

Evaluation of suicidality during pharmacologic treatment of mood and non-mood

disorders

Ann Clin Psychiatry 5:209-224; 1993

77. Beasley C, Holman S, Potvin J

Fluoxetine compared with imipramine in the treatment of inpatient depression : a

multicenter trial

Ann Clin Psychiatry 5:199-207; 1993

78. Beasley C, Sayler M, Potvin J

Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial

Intl Clin Psychopharmacol 8:143-149; 1993

79. Heiligenstein J, Beasley C, Potvin J

Fluoxetine not associated with increased aggression in controlled clinical trials

Intl Clin Psychopharmacol 8:277-280; 1993

80. Beasley C, Potvin J

Fluoxetine: activating and sedating effects

Intl Clin Psychopharmacol 8:271-275; 1993

Page 17: Resume-CV 1_May_2015

17

81. Bergstrom R, Beasley C, Levy N, Blumenfield M, Lemberger L

A review of the effects of renal and hepatic disease on the pharmacokinetics, renal

tolerance, and their risk-benefit profile of fluoxetine

Intl Clin Psychopharmacology 8:261-266; 1993

82. Beasley C, Masica D, Heiligenstein J, Wheadon D, Zerbe R

Possible monoamine oxidase inhibitor – serotonin uptake inhibitor interaction: fluoxetine

clinical data and preclinical findings

J Clin Psychopharmacol 13:312-320; 1993

83. Goldstein D, Rampey A, Potvin J, Masica D, Beasley C

Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for

weight reduction

J Clin Psychiatry 54:309-316; 1993

84. Heiligenstien J, Coccaro E, Potvin J, Beasley C, Dornseif B, Masica D

Fluoxetine not associated with increased violence or aggression in controlled clinical

trials

Ann Clin Psychiatry 4:285-295; 1992

85. Beasley C, Sayler M, Weiss A, Potvin J

Fluoxetine: activating and sedating effects at multiple fixed doses

J Clin Psychopharmacol 12:328-333; 1992

86. Wheadon D, Rampey A, Thompson V, Potvin J, Masica D, Beasley C

Lack of association between fluoxetine and suicidality in bulimia nervosa

J Clin Psychiatry 53:235-241; 1992

87. Beasley C, Dornseif B, Bosomworth J, Sayler M, Rampey A, Heiligenstein J, Thompson V,

Murphy D, Masica D

Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression

Intl Clin Psychopharmacol 6:Suppl 6:53-75; 1992

88. Beasley C, Masica D, Potvin J

Fluoxetine: a review of receptor and functional effects and their clinical implications

Psychopharmacology 107:1-10; 1992

89. Beasley C, Potvin J, Masica D, Wheadon D, Dornseif B, Genduso L

Fluoxetine: no association with suicidality in obsessive-compulsive disorder

J Affective Disorders 24:1-10; 1992

90. Beasley C, Dornseif B, Bosomworth J, Sayler M, Rampey A, Heiligenstien J, Thompson V,

Murphy D, Masica D

Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression

BMJ 303:685-692; 1991

Page 18: Resume-CV 1_May_2015

18

91. Beasley C, Poltz J, Dornseif B, Bosomworth J, Sayler M

Fluoxetine versus trazodone: efficacy and activating-sedating effects

J Clin Psychiatry 52:294-99; 1991

92. Beasley C, Sayler M, Bosomworth J, Wernicke J

High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded

depression

J Clin Psychopharmacol 11:166-174; 1991

93. Usher R, Beasley C, Bosomworth J

Efficacy and safety of morning versus evening fluoxetine administration

J Clin Psychiatry 52:134-136; 1991

94. Beasley C, Sayler M, Cunningham G, Weiss A, Masica D

Fluoxetine in tricyclic refractory major depressive disorder

J Affective Disorders 20:193-200; 1990

95. Beasley C, Bosomworth J, Wernicke J

Fluoxetine: relationships among dose, response, adverse events, and plasma

concentrations in the treatment of depression

Psychopharm Bull 26:18-24; 1990

96. McCombs J, Nichol M, Stimmel G, Sclar D, Beasley C, Gross L

The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in

a Medicaid population

J Clin Psychiatry 51:6, suppl:60-69; 1990

97. Beasley C, Magnusson M, Garver D

TSH response to TRH and haloperidol response latency in psychoses

Biol Psychiatry 24:423-31; 1988

LETTERS

1. Beasley C

Response (letter).

Aust N Z J Psychiatry 33:12-122; 1999.

2. Perry PJ, Sanger T, Beasley CM

Plasma olanzapine and clinical response (Response letter).

J Clin Psychopharmacol 19:193-194; 1999.

3. Beasley C

Response (letter).

Page 19: Resume-CV 1_May_2015

19

Br J Psychiatry 175:391-392; 1999.

4. Beasley C

Response (letter).

CNS Drugs 9:513-515; 1998.

5. Beasley C

Response (letter).

Neuropsychopharmacol 16:89-90; 1997.

6. Beasley C

Fluoxetine-Dopaminergic Interaction Data (letter).

J Clin Psychiatry 55:77-78; 1994.

7. Masica D, Beasley C, Kotsanos J, Potvin J

Trend in suicide rates since fluoxetine introduction (letter).

Am J Pub Health 82:1295; 1992.

8. Beasley C

Reply (letter).

J Clin Psychopharmacol 12:220-221; 1992.

9. Beasley C

Fluoxetine and suicide (letter).

BMJ 303:1200; 1991.

10. Fuller R, Beasley C

Fluoxetine: mechanism of action (letter).

J Am Acad Child Adolesc Psychiatry 30:849-850; 1991.

11. Beasley C

Correction to ‘Fluoxetine Overdose: A Case Report’ (letter).

J Anal Tox 14:63; 1990.

ABSTRACTS AND POSTERS (SELECTED)

1. Camporeale A, Beasley C, Tanaka Y, D’Souza D, Upadhyaya H

Changes in blood pressure and heart rate associated with atomoxetine treatment in

attention-deficit/hyperactivity disorder

Euro Neuropsychopharmacol 22:429-430; 2012.

2. Gatz JL, Jamal HH, Plewes JM, Case MG, Beasley CM

Treatment-resistant major depressive disorder: comparison of acute (2-week) safety

endpoints after switching treatment from other antidepressants to olanzapine/fluoxetine

combination therapy

Page 20: Resume-CV 1_May_2015

20

Annual Meeting of the American College of Neuropsychopharmacology. Holywood, FL, Dec. 7,

2009.

3. Beasley CM, Disch D, Chen W, Witte M, Acharya N, Perahia D, Nilsson, M, Perlis R

Potential risk factors for development of treatment-emergent suicidal ideation in the

duloxetine placebo-controlled major depressive disorder database

Annual Meeting of the American College of Neuropsychopharmacology. Boca Raton,

FL, Dec. 12, 2007.

4. Beasley CM, Disch D, Prabhakar V, Desiah D, Tamura R, Perlis R

Potential predictive factors for development of treatment-emergent suicidal ideation in the

fluoxetine placebo-controlled major depressive disorder database

Neuropsychopharmacol 31:S1:100-101; 2006.

5. Acharya NV, Rosen AS, Polzer JP, DSouza DN, Perahia DG, Cavazzoni PA, Beasley CM,

Baldessarini RJ

Duloxetine: meta-analysis of suicidal behaviors and thoughts in clinical trials for major

depressive disorder

Neuropsychopharmacol 30:S1:S97; 2005.

6. Beasley CM, Sutton VK, Taylor C, Sethuraman G, Dossenbach M, Naber D, Pickar D

Does maintenance treatment with atypical antipsychotics worsen quality of life among

stable patients with schizophrenia?

Neuropsychopharmacol 30:S1:S189; 2005.

7. Beasley C, Stauffer V, Liu-Seifert H, Rock S, Mitchell C, Dunayevich E, Davis J, Breier A

Overall treatment effectiveness as measured by time continuing on antipsychotic therapy

Neuropsychopharmacol 29:S1:S106; 2004.

8. Beasley C, Acharya N, Polzer J, Nilsson M, Rosen A, Cavazzoni P

Nomenclature for suicide-related thoughts and behaviors

American Academy of Child and Adolescent Psychiatry. Washington, DC, Oct. 21, 2004.

9. Beasley CM, Sowell MO, Carlson C, Mukhnopadhyay N, Dannanberg j, Henry R, Breier A,

Cavazzoni P

Prospective evaluation of insulin sensitivity by the hyperinsulinemic, euglycemic clamp in

healthy volunteers treated with olanzapine, risperidone or placebo

Schizophrenia Res 60:309, 2003.

10. Beasley C, Sowell M, Henry R, Carlson C, Mukhopadhyay N, Dananberg J, Cavazzoni P, Breier

A

Prospective evaluation of insulin sensitivity by the hyperinsulinemic, euglycemic clamp in

healthy volunteers treated with olanzapine, risperidone, or placebo

Page 21: Resume-CV 1_May_2015

21

Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR, Dec. 11,

2002.

11. Czekalla J, Beasley C, David S, Berg P, Stauffer V, Boylan C

Cardiac conduction in females under intramuscular (IM) and oral olanzapine from

schizophrenia clinical trials ECGs

Euro Neuropsychopharmacol 12:S3:S291-292; 2002.

12. Tohen  M, David RS, Beasley CM, Alaka K

QT intervals: IM olanzapine treatment in acutely agitated patients

European Psychiatry 17:105; 2002.

13. Beasley C, Sowell M, Cavazzoni P, Breier A, Steinberg H, Dananberg J

Assessment of insulin secretory responses using the hyperglycemic clamp in normal

subjects treated with olanzapine, risperidone, or placebo

Annual Meeting of the American College of Neuropsychopharmacology

Kona, HA, Dec. 10, 2001.

14. Beasley CM, Hamilton SH, Dossenbach M

Relapse prevention with olanzapine

Schizophrenia Res 41:196-197; 2000.

15. Czekalla J, Dellva MA, Berg PH, Grundy SL, Beasley CM

Cardiac safety profile of olanzapine based on preclinical and clinical ECG data

Schizophrenia Res 41:195; 2000.

16. Beasley C, Berg P, Dananberg J, Kwong K, Taylor C, Breier A

Incidence and rate of treatment-emergent potential impaired glucose tolerance and

potential diabetes with olanzapine compared to other antipsychotic agents and placebo

Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR, Dec. 11,

2000.

17. Jones B, Wang H, David S, Nisivoccia J, Beasley C, Feldman P, Meehan K

A double-blind, placebo controlled study of short-acting intramuscular olanzapine and

lorazepam in acutely agitated patients with dementia

Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR, Dec. 13,

2000.

18. Beasley CM, Hamilton SH, Dossenbach M

Relapse prevention with olanzapine

Euro Neuropsychopharmacol 10:304; 2000.

19. Crumb W, Beasley C, Thornton A, Breier A

Cardiac ion channel blocking profile of olanzapine and other antipsychotics

Page 22: Resume-CV 1_May_2015

22

Annual Meeting of the American College of Neuropsychopharmacology. Alcapulco, Mexico, Dec.

13, 1999.

20. Tran PV, Basson BR, Kennedy JS, Beasley CM, Bymaster FP, Tollefson GD

The comparative anti-muscarinic-like side effect profiles of olanzapine and risperidone

treatment in patients with schizophrenia spectrum psychosis

Euro Neuropsychopharmacol 9:290-291; 1999.

21. Schmidt M, Michelson D, Beasley CM, Kopp J, Koke S

Long term treatment outcomes of highly anxious depressed patients: evidence from a 52-

week trial with fluoxetine

Euro Neuropsychopharmacol 9:209; 1999.

22. Basson B, Kennedy J, Tran P, Beasley C, Bymaster F, Tollefson G

The comparative anti-muscarinic-like side effect profiles of olanzapine and risperidone

treatment in patients with schizophrenia spectrum psychosis

Annual meeting of the American College of Neuropsychopharmacology. Las Croabas, Puerto

Rico, PR, Dec. 15, 1998.

23. Beuzen J, Birkett M, Kiesler G, Tollefson G, Wood A, Beasley C

Olanzapine vs clozapine: an international double-blind study in treatment resistant

schizophrenia

Annual meeting of the American College of Neuropsychopharmacology. Las Croabas, PR, Dec.

16, 1998.

24. Tamura R, Michelson D, Sundell K, Beasley C

Adverse event profiles associated with long-term fluoxetine treatment

American Psychiatric Association Annual Meeting. Toronto, Canada, June 3, 1998.

25. Beasley C, Tollefson G, Dellva M, Tamura R, Glazer W, Morgenstern H

The differential risk of tardive dyskinesia with olanzapine

American Psychiatric Association Annual Meeting. Toronto, Canada, June 2, 1998.

26. Wright P, Tollefson G, Beasley C, Tamura R, Tran P, Potvin J

A blinded, controlled, long-term study of the comparative incidence of treatment-emergent

tardive dyskinesia with olanzapine or haloperidol

Schizophrenia Res 29:206; 1998.

27. Jones B, Crawford A, Beasley C, Tollefson G

The acute and long-term effect of olanzapine compared with placebo and haloperidol on

serum prolactin concentration

Schizophrenia Res 29:204-205; 1998.

Page 23: Resume-CV 1_May_2015

23

28. Tamura R, Beasley C, Dellva M, Glazer W, Morgenstern H, Tollefson G

What is the differential risk of tardive dyskinesia with the novel antipsychotic olanzapine?

Schizophrenia Res 29:176; 1998.

29. Reams S, Sanger T, Beasley C

Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic

disorders

Schizophrenia Res 29:151-152, 1998.

30. Tran P, Lu Y, Sanger T, Beasley C, Tollefson G

Olanzapine in the treatment of schizoaffective disorder

Schizophrenia Res 29:151; 1998.

31. Beasley CM, Sayler ME, Kiesler GM, Potvin JH, Sanger TM, Tollefson GD

The influence of pharmacotherapy on self-directed and externally-directed aggression in

schizophrenia

Schizophrenia Res 29:28; 1998.

32. Tollefson G, Sanger T, Beasley C

A blinded trial on the course and relationship of depressive symptoms in schizophrenia

Annual meeting of the American College of Neuropsychopharmacology. Kona, HA, Dec. 8, 1997.

33. Tran P, Tollefson G, Beasley C, Crawford A

From molecule to marketplace: profile of the atypical antipsychotic olanzapine

Annual meeting of the American College of Neuropsychopharmacology. Kona, HA, Dec. 10,

1997.

34. Beasley C, Tollefson G, Dellva M, Tamura R, Glazer W, Morgenstern H

What is the differential risk of tardive dyskinesia with the atypical antipsychotic

olanzapine?

Annual meeting of the American College of Neuropsychopharmacology. Kona, HA, Dec. 10,

1997.

35. Dellva M, Tamura R, Glazer W, Morgenstern H, Beasley C

What is the differential risk of tardive dyskinesia with the atypical antipsychotic

olanzapine?

Euro Neuropsychopharmacol 7:199-200; 1997.

36. Crawford A, Beasley C, Tollefson G

The acute and long-term effect of olanzapine compared with placebo and haloperidol on

serum prolactin concentration

Euro Neuropsychopharmacol 7:199; 1997.

37. Crawford A, Gomez J, Beasley C, Tollefson G

Olanzapine versus haloperidol: analysis of schizophrenic patients from the multi-center

Page 24: Resume-CV 1_May_2015

24

international trial

Euro Neuropsychopharmacol 7:199; 1997.

38. Conley R, Tamminga C, Beasley C

Olanzapine vs. Chlorpromazine in treatment resistant schizophrenia

Annual meeting of the American College of Neuropsychopharmacology. San Juan, PR; Dec. 12,

1996.

39. Tran P, Dellva M, Rampey V, Tollefson G, Beasley C

Long-term continuation therapy with the novel antipsychotic olanzapine: a review of the

clinical experience

Euro Neuropsychopharmacol 6:115; 1996.

40. Kuntz A, Tran P, Dellva M, Sanger T, Beasley C, Tollefson G

Acute phase efficacy and safety of olanzapine: a review

Euro Neuropsychopharmacol 6:115; 1996.

41. Dellva M, Satterlee W, Tran P, Beasley C, Greaney M, Tollefson G

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in acute

treatment

Euro Neuropsychopharmacol 6:106; 1996.

42. Lu Y, Sanger T, Beasley C, Tran P, Tollefson G

Olanzapine in the treatment of schizoaffective disorder

European Neuropsychopharmacology 6:106; 1996.

43. Tollefson G, Sanger T, Beasley C

The course of primary and secondary negative symptoms in a placebo- and comparator-

controlled trial of the atypical antipsychotic olanzapine

Euro Neuropsychopharmacol 6:14; 1996.

44. Beasley C, Tran P, Satterlee W, Tollefson G, Lu Y, Kuntz A, Bradley P, Paul S

Olanzapine versus placebo, results of the United States double-blind olanzapine trial

Euro Neuropsychopharmacol 6:58; 1996.

45. Quicken FM, Stewart JW, McGrath PJ, Beasley C

Pattern analysis predicts relapse on fluoxetine and placebo during continuation

Euro Neuropsychopharmacol 6:153-154; 1996.

46. Tran P, Beasley C, Tollefson G, Dellva M, Hamilton S,Van Ostrand R, Paul S

Acute and long-term results of the North American double-blind olanzapine trial

Euro Neuropsychopharmacol 6:59; 1996

47. Martin C, Genduso L, Revicki D, Hamilton S, Tran P, Beasley C

Quality of life outcomes of olanzapine, a new atypical antipsychotic agent

Schizophrenia Res 18:130-131; 1996.

Page 25: Resume-CV 1_May_2015

25

48. Tollefson GD, Beasley CM, Tran PV, Tamura RN, Sanger TM, Wood A, Beuzen JN

Olanzapine versus haloperidol: results of the multi-center international trial

Schizophrenia Res 18:131; 1996.

49. Tran P, Dellva M, Street J, Beasley C, Tollefson G, Kiesler G

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in acute

treatments

World Congress of Psychiatry. Madrid, Spain; Aug. 26, 1996.

50. Dellva M, Tran P, Beasley C, Cousins L, Krueger J, Tollefson G

Clinical experience with long-term continuation treatment with olanzapine

World Congress of Psychiatry. Madrid, Spain; Aug. 25, 1996.

51. Beasley C

Olanzapine safety overview

World Congress of Psychiatry. Madrid, Spain, Aug. 23, 1996.

52. Tollefson G, Sanger T, Beasley C

The course of primary and secondary negative symptoms in a controlled trial with

olanzapine

CINP. Melbourne, Australia, June 26, 1996.

53. Tran P, Beasley C, Tollefson G, Dellva M, Hamilton S, Van Ostrand R, Paul S

Acute and long-term results of the North American double-blind olanzapine trial

CINP. Melbourne, Australia, June 25, 1996.

54. Tran P, Beasley C, Street J, Tamura R, Dellva M, Graffeo K, Kruger J, Tollefson G

Olanzapine versus haloperidol: acute results of the multi-center international trail

CINP. Melbourne, Australia, June 25, 1996.

55. Beasley C, Tran P, Beuzen J, Tamura R, Dellva M, Bailey J, Kruger J, Tollefson G

Olanzapine versus haloperidol: long-term results of the international trial

CINP. Melbourne, Australia, June 25, 1996.

56. Beasley C, Tran P, Satterlee W, Tollefson G, Lu Y, Kuntz A, Bradley P, Paul S

Olanzapine versus placebo, results of the United States double-blind olanzapine trial

CINP. Melbourne, Australia, June 25, 1996.

57. Tran P, Beasley C, Tollefson G, Satterlee W, Small J, Besancon G, Naber D, Sanger T, Bailey J,

Wood A, Graffeo K, Meltzer H

Olanzapine in the treatment of schizophrenia and other psychotic disorders

NCDEU Annual Meeting. Boca Raton, FL, May 24, 1996.

58. Satterlee W, Beasley C, Sanger T, Tollefson G

a clinical update on olanzapine: atypical antipsychotic

NCDEU Annual Meeting. Boca Raton, FL, May 23, 1996.

Page 26: Resume-CV 1_May_2015

26

59. Crawford A, Beasley C, Tollefson G

Olanzapine: impact of an atypical antipsychotic candidate on prolactin release

American Psychiatric Association Annual Meeting. New York, NY, May 9, 1996.

60. Patel B, Kurtz D, Callaghan J, Beasley C, Bergstrom R

Effect of smoking and gender on population pharmacokinetics of olanzapine

American Psychiatric Association Annual Meeting. New York, NY, May 8, 1996.

61. Tran P, Dellva M, Beasley C, Satterlee W, Cousins L, Tollefson G

Clinical experience with long-term continuation treatment with olanzapine

American Psychiatric Association Annual Meeting. New York, NY, May 8, 1996.

62. Satterlee W, Beasley C, Tran P, Tamura R, Krueger J, Tollefson G

Olanzapine versus haloperidol: results of a large multicenter international trial

American Psychiatric Association Annual Meeting. New York, NY, May 8, 1996.

63. Tollefson G, Sanger T, Beasley C

The course of primary and secondary negative symptoms in a controlled trial with

olanzapine

American Psychiatric Association Annual Meeting. New York, NY, May 8, 1996.

64. Beasley C, Tollefson G, Tran P, Satterlee W, Sanger T

Olanzapine: molecule to drug candidate

American Psychiatric Association Annual Meeting. New York, NY, May 7, 1996.

65. Beasley C, Tran P, Tamura R, Tollefson G

Olanzapine versus haloperidol: results of the multi-center international trial

Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR, Dec. 15,

1995.

66. Tran P, Beasley C, Dellva M, Cousins L, Gusman S, Tollefson G

Long-term efficacy and safety of olanzapine

Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR Dec. 13,

1995.

67. Tran P, Beasley C, Crawford A, Hamilton S, Tollefson G

Acute and long-term results of the North American double-blind olanzapine trial

Belgian College of Neuropsychopharmacology and Biological Psychiatry (BCNBP). Kortenberg,

Belgium, Dec. 1, 1995.

68. Tollefson G, Beasley C, Tran P, Sanger T

Olanzapine: an exciting atypical antipsychotic-the clinical experience

European College of Neuropsychopharmacology Annual Meeting. Venice, Italy, Oct. 1, 1995.

Page 27: Resume-CV 1_May_2015

27

69. Dittmann R, Beasley C, Geuppert M, Muhlenbacher

Clinical efficacy and safety of olanzapine: results from a double blind-multinational trial

Pharmacopsychiatry 28:172; 1995.

70. Beuzen J, Tran P, Beasley C, Tollefson G, Sanger T, Hamilton S

Clinical efficacy and safety of increasing doses of olanzapine, a new “atypical”

antipsychotic agent

CINP Regional Conference. Vienna, Austria and Prague, Czech Republic, June 10, 1995.

71. Beuzen J, Tran P, Beasley C, Tollefson G, Sanger T

Clinical efficacy and safety of olanzapine, a new “atypical” antipsychotic agent

CINP Regional Conference. Vienna, Austria and Prague, Czech Republic, June 10, 1995.

72. Beuzen J, Beasley C, Tran P, Sanger T, Paul S, Tollefson G

Additional clinical experience with olanzapine, an “atypical” antipsychotic

CINP Regional Conference. Vienna, Austria and Prague, Czech Republic, June 10, 1995.

73. Tran P, Beasley C, Tollefson G, Crawford A, Paul S

Olanzapine: an update on recent clinical studies

NCDEU Annual Meeting. Orlando, FL, June 1, 1995.

74. Tollefson G, Beasley C, Tran P, Satterlee W, Lu Y, Mesters P, Gomez J, Dittman R, Beuzen J,

Graffeo K, Kolling C, Paul S

Olanzapine in the treatment of schizophrenia and other psychotic disorders

NCDEU Annual Meeting. Orlando, FL, May 31, 1995.

75. Tollefson G, Beasley C, Tran P, Sanger T

The next generation of antipsychotics

American Psychiatric Association Annual Meeting. Miami, FL, May 24, 1995.

76. Satterlee W, Beasley C, Sanger T, Tollefson G

Additional clinical experience with olanzapine, an atypical antipsychotic

American Psychiatric Association Annual Meeting. Miami, FL, May 24, 1995

77. Tran P, Beasley C, Tollefson G, Blin O, Hamilton S, Wharton I, Cousins L, Kiesler G, Greaney M,

Gussman S

Clinical efficacy and safety of increasing doses of olanzapine: a new “atypical”

antipsychotic agent

American Psychiatric Association Annual Meeting. Miami, FL, May 23, 1995.

78. Tran P, Beasley C, Tollefson G, Satterlee W, Small J, Besancon G, Naber D, Sanger T, Bailey J,

Graffeo K, Wood A, Meltzer H

Olanzapine in the treatment of schizophrenia and other psychotic disorders

American Psychiatric Association Annual Meeting. Miami, FL, May 23, 1995.

Page 28: Resume-CV 1_May_2015

28

79. Beasley C, Tran P, Tollefson G, Satterlee W, Crawford A, Wharton I, Luttman C, Voegele T

Long-term efficacy and safety of olanzapine: a novel “atypical” antipsychotic agent

American Psychiatric Association Annual Meeting. Miami, FL, May 23, 1995.

80. Beasley C, Tollefson G, Tran P, Satterlee W

Olanzapine: a potential atypical antipsychotic

American Psychiatric Association Annual Meeting. Miami, FL, May 23, 1995.

81. Tran P, Beasley C, Tollefson G, Beuzen J, Holman S, Sanger T, Satterlee W

Olanzapine: a promising “atypical” antipsychotic agent

Schizophrenia Res 15:169; 1995.

82. Saterlee W, Beasley C, Sanger T, Tollefson G

Additional clinical experiences with olanzapine an “atypical” antipsychotic

Schizophrenia Res 15:163; 1995.

83. Satterlee W, Beasley C, Sanger T, Tran P, Paul S, Tollefson G

Olanzapine a new “atypical” antipsychotic

Schizophrenia Res 15:163-164; 1995.

84. Tollefson G, Sanger T, Beasley C, Tran P

Is there a relationship between EPSE and efficacy: fact or fiction

Scientific Council of the International Academy for Biomedical and Drug Research. Florence,

Italy, Mar. 11, 1995.

85. Beuzen J, Beasley C, Satterlee W, Sanger T, Paul S, Tollefson G

Additional clinical experience with olanzapine, an “Atypical” Antipsychotic

Critical Issues in the Treatment of Schizophrenia Workshop. Florence, Italy, Mar. 11, 1995.

86. Tran PV, Beasley CM, Tollefson GD, Beuzen JN, Dellva MA, Sanger TM, Paul S

Acute and long-term results of the North American double-blind olanzapine trial

Euro Neuopsychopharmacol 5:347-348; 1995.

87. Amsterdam JD, Hornig-Rohan M, Rosenbaum JF, Quitkin FM, Fawcette J, Reimherr FW,

Beasley CM

Fluoxetine and norfluoxetine levels in major depression

Biological Psychiatry 37:606; 1995.

88. Tollefson GD, Beasley CM, Tran PV, Sanger T

Olanzapine: a novel antipsychotic with broad spectrum profile

Biological Psychiatry 35:746-747; 1994.

89. Tran P, Beasley C, Satterlee W

Sanger T, Holman S, Tollefson G

Olanzapine: a potential novel antipsychotic agent

Page 29: Resume-CV 1_May_2015

29

Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR, Dec. 14,

1994.

90. Tran P, Beasley C, Tollefson G, Beuzen J, Holman S, Sanger T, Satterlee W

Olanzapine: a promising “atypical” antipsychotic agent

Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR, Dec. 14,

1994.

91. Beasley C, Satterlee W, Sanger T, Paul S, Tollefson G

Additional clinical experiences with olanzapine an “atypical” antipsychotic

Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR, Dec. 14,

1994.

92. Satterlee W, Beasley C, Sanger T, Tran P, Paul S, Tollefson G

Olanzapine a new “atypical” antipsychotic

Annual Meeting of the American College of Neuropsychopharmacology. San Juan. Dec. 14,

1994.

93. Tran P, Beasley C, Tollefson G, Holman S

Clinical efficacy and safety of olanzapine: a novel antipsychotic agent

European College of Neuropsychopharmacology Annual Meeting. Jerusalem, Israel, Oct. 18,

1994.

94. Tran P, Beasley C, Tollefson G, Beuzen J, Holman S, Sanger T, Satterlee W

Olanzapine: a promising “atypical” antipsychotic agent

European College of Neuropsychopharmacology Annual Meeting. Jerusalem, Israel, Oct. 18,

1994.

95. Wood A, Beasley C, Tollefson G, Tran P

Efficacy of olanzapine in the positive and negative symptoms of schizophrenia

Euro Neuropsychopharmacol 4:224; 1994.

96. Tran P, Beasley C, Tollefson G, Beuzen J, Holman S, Sanger T

Olanzapine: a promising “atypical” antipsychotic agent

Plan Asian-Pacific Conference on Mental Health. Beijing, China, Oct. 12, 1994.

97. Tran P, Beasley C, Tollefson G, Satterlee W, Sanger T

Clinical efficacy and safety of olanzapine: a potential atypical antipsychotic agent

Pan Asian-Pacific Conference on Mental Health. Beijing, China, Oct 12, 1994.

Page 30: Resume-CV 1_May_2015

30

98. Satterlee W, Beasley C, Sanger T, Tollefson G

A clinical update on olanzapine, an “atypical” antipsychotic

Institute on Hospital and Community Psychiatry Annual Meeting. San Diego, CA, Oct. 3, 1994.

99. Satterlee W, Beasley C, Tollefson G, Moore N, Tran P, Sanger T

Preclinical and clinical observations of olanzapine (a new antipsychotic agent)

Schizophrenia 1994: 3rd International Conference. Vancouver, Canada, Aug. 23, 1994.

100. Tran P, Beasley C, Tollefson G, Sanger T, Satterlee W

Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent

Neuropsychopharmacol 10:3S, Part 2:267S; 1994.

101. Beasley C, Tollefson G, Moore N, Tye N

Olanzapine: the new “atypical” antipsychotic agent

Neuropsychopharmacol 10:3S, Part 1:536S; 1994.

102. Satterlee W, Beasley C, Tollefson G, Moore N, Tran P

Preclinical and clinical observations of olanzapine (a new antipsychotic)

NCDEU Annual Meeting. Marco Island, FL, June 2, 1994.

103. Rosenbaum J, Fava M, Quitkin F, Fawcett J, Amsterdam J, Reimherr F, Beasley C

Time to remission of depression with acute fluoxetine treatment

NCDEU Annual Meeting. Marco Island, FL, June 2, 1994.

104. Tran P, Beasley C, Tollefson G, Sanger T, Satterlee W

Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent

Canadian College of Neuropsychopharmacology Annual Meeting. Montreal, Canada, May 31,

1994.

105. Tran P, Beasley C, Tollefson G, Sanger T, Satterlee W

Clinical efficacy and safety of olanzapine: a new atypical Antipsychotic agent

American Psychiatric Association Annual Meeting. Philadelphia, PA, May 24, 1994.

106. Beasley C, Tollefson G, Tran P, Satterlee W

Olanzapine: a potential atypical antipsychotic

American Psychiatric Association Annual Meeting. Philadelphia, PA, May 24, 1994.

107. Beasley C, Tollefson G, Moore N

Olanzapine: a new “atypical” antipsychotic agent

Eighth Triannual Congress of the Israel Psychiatric Association. Tiberias, Israel, May 3, 1994.

108. Rosenbaum J, Quitkin F, Fava M, Amsterdam J, Fawcett J, Zajecka J, Lebegue B,

Reimherr F, Beasley C

Fluoxetine vs. Placebo: long-term treatment of MDD

Annual Meeting of the American College of Neuropsychopharmacology. Honolulu, HA, Dec. 15,

1993.

Page 31: Resume-CV 1_May_2015

31

109. Beasley C, Tollefson G, Tye N, Moore N

Olanzapine: a potential “atypical” antipsychotic agent

Annual Meeting of the American College of Neuropsychopharmacology. Honolulu, HA, Dec. 15,

1993.

110. Sayler M, Pande A, Beasley C, Tollefson G

Antidepressant efficacy and severity of depression

American Psychiatric Association Annual Meeting. San Francisco, CA, May 26, 1993.

111. Tye N, Moore N, Rees G, Sanger G, Calligaro D, Beasley C

Preclinical pharmacology of olanzapine: a novel ‘atypical’ antipsychotic agent

Second International Conference on Schizophrenia. Vancouver, Canada, July 21, 1992.

112. Beasley C, Montgomery S, Tye N

Olanzapine: an open-label study in schizophrenia

Second International Conference on Schizophrenia. Vancouver, Canada, July 21, 1992.

113. Beasley C, Sayler M

Fluoxetine: activating and sedating effects at multiple fixed doses

CINP. Nice, France, June 29, 1992.

114. Bergstrom R, Beasley C, Levy N, Dubey A, Blumenfield M, Goodman A, Solomon R

Fluoxetine pharmacokinetics after daily doses of 20 mg fluoxetine in patients with severely

impaired renal function

Pharmaceutical Research 8:S294; 1991.

115. Heiligenstein J, Coccaro E, Potvin J, Beasley C, Dornseif B, Masica D

Fluoxetine not associated with violent behavior in controlled clinical trials

Clinical Research 39:768A; 1991.

116. Beasley C, Faries D, Sayler M, Potvin J

Fluoxetine not associated with suicidality in international controlled clinical trials in

depression

Clinical Research 39:767A; 1991.

117. McDermott B, Beasley C, Kelly K, Hirschowitz J, Garver D

Confounds of neuroendocrine challenge tests

American Psychiatric Association Annual Meeting. Montreal, Canada, May 10, 1988.

118. Garver D, Beasley C, Kelly K, Magnusson M, Johnson C, Chopra Y

Antipsychotic response latencies: separate diseases

American Psychiatric Association Annual Meeting. Montreal, Canada, May 9, 1988.

119. Garver D, Beasley C, Sautter F, Chopra Y

Early antipsychotic response with neuroleptics and dopamine psychosis

Page 32: Resume-CV 1_May_2015

32

Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR, Dec. 8,

1987.

120. Sautter F, McDermott B, Beasley C

Short-term outcome of schizophreniform disorder

American Psychiatric Association Annual Meeting. Chicago, IL, May 12, 1987.

121. Beasley C, Garver D

Growth hormone response and neuroleptic response in neuroleptic naïve patients

American Psychiatric Association Annual Meeting. Chicago, IL, May 12, 1987.

122. Beasley C, Magnusson M, Garver D

TSH response to TRH and haloperidol response latency in psychoses

Society for Biological Psychiatry Annual Meeting. Chicago, IL, May 7, 1987.

GRANT REPORTS

1. Anderson J, Kline P, Beasley C

A theory of the acquisition of cognitive skills

Technical Report 77-1. Yale University, 1978

2. Anderson J, Kline P, Beasley C

Complex learning processes

Technical Report 78-1. Yale University, 1978

INVITED PRESENTATIONS (SELECTED)1. Beasley C

A tale of two profiles: the hemodynamic effects of atomoxetine under clinical observation vs. intensive monitoringCardiac Safety Research Consortium – Pediatric Cardiovascular Safey Drug and Medical Device Development Thinktank. Silver Spring, MD, Dec. 10, 2010.

2. Beasley CHow to characterize the QT effect in the targeted patient population when a TQT study is positiveDIA Conference: Cardiovascular Safety in Drug Development: QT, Arrhythmias, Thrombosis, and Bleeding. Arlington, VA, Apr. 12, 2009.

3. Beasley CRegulatory, procedural, and statistical considerations in the thorough QT study: the complexity of the design of a thorough QT studyWorld Pharmaceutical Congress. Philadelphia, PA, May 12, 2008.

4. Beasley CConduct & Design of a TQT StudyKeynote address. QT and Drug Development. London, England, Oct. 24, 2007.

Page 33: Resume-CV 1_May_2015

33

5. Beasley CEffective strategies for designing thorough QT studieseXlpharma webinar. Sept. 27, 2007.

6. Beasley CWhy we need improved preclinical predictors and human biomarkers for torsades de pointeKeynote presentation, Cardiac Safety. World Pharmaceutical Congress. Philadelphia, PA, June 12, 2007.

7. Beasley CIs 36,000 ECGs overkill?DIA Conference – Challenges and Practical Aspects of Assessing Clinical QT Prolongation / Proarrhythmia Risk and Implications for the Critical Pathway. Washington, DC, May 9, 2006.

8. Beasley CDo we need a new ear, a new purse, or both? OR What do we need to more effectively and efficiently confirm the absence of risk of torsades?Cardiac Safety and Critical Pathway Initiative Regulatory Think-Tank. Bethesda, MD, Oct. 11, 2005.

9. Beasley CDrug development from the industry perspective: challenges and opportunitiesA Workshop on Clinical Trials in Psychopharmacology. New York, NY, Apr. 12, 2005.

10. Beasley COlanzapineBritish Association for Psychopharmacology Regional Meeting. Guilford, England, Oct. 10, 1997.

11. Beasley COlanzapine: atypical antipsychoticAmerican Society of Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL, Mar. 21, 1996.

12. Beasley COlanzapine clinical development: molecule to drug candidateNCDEU Annual Meeting. Orlando, FL, June 1, 1995.

13. Beasley CClinical trial design in depression and anxietyPMA Education and Research Institute Course Drug Development in Depression and Anxiety. Boston, MA, Mar. 15, 1994.

14. Beasley CAtypical antipsychotics: What are they?Grand Rounds, Cleveland Clinic. Cleveland, OH, Nov. 4, 1993.

15. Beasley COlanzapineInternational Congress on Schizophrenia Research. Colorado Springs, CO, Apr. 20, 1993.

16. Beasley CFluoxetine in tricyclic refractory major depressive disorderSecond International Conference on Refractory Depression. Amsterdam, The Netherlands, June 26, 1992.

17. Beasley CFluoxetine: significance of plasma concentrations and impact on psychomotor performance

Page 34: Resume-CV 1_May_2015

34

1992 Annual Lectureship in Forensic Toxicology. Annual meeting of the American Academy of Forensic Sciences. New Orleans, LA, Feb. 21, 1992.

18. Beasley C, Farries DFluoxetine: worldwide suicidality dataAnnual Meeting of the American College of Neuropsychopharmacology  (Study Group). San Juan, PR, Dec. 11, 1991.

19. Beasley C, Farries DStrategies to lower placebo response rates in depressed patients in antidepressant trialsAnnual Meeting of the American College of Neuropsychopharmacology (Study Group). San Juan, PR, Dec. 9, 1991.

20. Beasley C, Dornseif BPlacebo response in depression: associated variables?Annual Meeting of the American College of Neuropsychopharmacology(Study Group). Maui, HA, Dec. 13, 1989.

21. Beasley CTSH response to TRH and differential drug response in psychosisFounder’s Day Resident Award Paper Presentation, Ohio Psychiatric Association. Toledo, OH, Apr. 23, 1988.

22. Beasley CMedication response subtyping of psychoses and neuroendocrine correlatesIndiana University Psychiatric Research Institute Seminar. Indianapolis, IN, Nov. 5, 1987.

23. Beasley CSerotonin uptake inhibitors in psychiatryAnnual Convention of the Central Neuropsychiatric Association. Indianapolis, IN, Oct. 10, 1987.

24. Beasley CTSH response to TRH and medication response subtypes of psychosesMaurice Levine Essay Award Presentation, Cincinnati Psychiatric Society. Cincinnati, OH, Apr. 15, 1987.

25. Garver D, Beasley CHeterogeneity of neuroleptic response in psychosis: implications for subtypingPsychiatric Research Society Annual Meeting. Tampa, FL, Apr. 4, 1987.

26. Beasley C, Garver DThe heterogeneity of schizophrenic illness(es)Annual Meeting & Scientific Symposium, Mental Health Association in Ohio. Columbus, OH, Oct. 10, 1986.

27. Beasley CThe acquisition of procedural knowledge: some linguistic examplesUniversity of Kentucky Linguistics Circle. Lexington, KY, Apr. 9, 1980.